Newsroom
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
Media Center
Press Release
Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
June 18, 2026
Read Now
Press Release
Scribe Therapeutics Awarded More Than $25 Million From CIRM to Accelerate Additional CRISPR-Based Gene Editing Therapies for Cardiometabolic Disease Into Clinical Trials
June 18, 2026
Read Now
Press Release
Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose
May 28, 2026
Read Now
Press Release
Scribe Therapeutics Presents Late-Breaking Preclinical Data Supporting STX-1150, a Clinical-Stage Epigenetic Silencing Therapy Designed to Achieve Years of LDL-C Lowering After a Single Dose
May 28, 2026
Read Now
Media
Scribe advances safer CRISPR therapies for heart health
May 22, 2026
Longevity.Technology
Read Now
Press Release
Scribe advances safer CRISPR therapies for heart health
May 22, 2026
Longevity.Technology
Read Now
Media
‘Unbelievably cool’: New therapy aims to lower ‘bad’ cholesterol before it turns deadly
May 22, 2026
Herald Sun
Read Now
Press Release
‘Unbelievably cool’: New therapy aims to lower ‘bad’ cholesterol before it turns deadly
May 22, 2026
Herald Sun
Read Now
Press Release
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
May 21, 2026
Read Now
Press Release
Scribe Therapeutics Achieves Regulatory Clearance to Initiate First-in-Human Clinical Study of STX-1150 for LDL-C Reduction
May 21, 2026
Read Now
Press Release
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
May 18, 2026
Read Now
Press Release
Scribe Therapeutics Reports Preclinical Data at ASGCT 2026 Demonstrating Enhanced Potency and Specificity of Engineered CRISPR Technologies for Epigenetic Silencing and Gene Editing
May 18, 2026
Read Now
Blog